LBRX

LB Pharmaceuticals Inc
CAPPED RATING

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

LB Pharmaceuticals Inc (LBRX) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (C+); its weakest is Revisions (F).

Quantitative Factor Evaluation • Updated

Overall Rating
1.8 / 5.0
D+
Value
C+
Factor Score 2.5 / 5.0
Growth
C-
Factor Score 1.9 / 5.0
Profitability
C-
Factor Score 2.0 / 5.0
Momentum
C+
Factor Score 2.8 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -7.4
EV / EBITDA -6.6
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -11.1%
Price Return 12M 165.7%
Catalyst Signal 0.00
Market Cap $1.4B
TTM Revenue N/A
Price / Sales N/A
ROE -38.8%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C+ (2.5) C- (1.9) C- (2.0) C+ (2.8) F (0.0) D+ (1.8)
2026-11-06 F (0.0) C- (1.9) C- (2.0) C+ (2.7) F (0.0) D (1.3)
2026-10-30 F (0.0) C- (1.9) C- (2.0) B- (3.1) F (0.0) D (1.4)
2026-10-23 F (0.0) C- (1.9) C- (2.0) B (3.3) F (0.0) D (1.4)
2026-10-16 F (0.0) C- (1.9) C- (2.0) B+ (3.8) F (0.0) D+ (1.5)
Page 1 of 3